PhoreMost and The Wistar Institute Collaborate to Identify New Druggable Targets
News Mar 11, 2016
PhoreMost Ltd has announced that it has entered into an alliance with The Wistar Institute to identify and de-orphan novel targets in cancer, aging and the immune system. The majority of disease driving targets are currently considered ‘undruggable’, because at first glance they appear structurally resistant to chemical intervention, especially when viewed outside of a cell in a static crystalized form.
PhoreMost has developed SITESEEKER®, a new ‘phenotypic’ screening platform that exploits the dynamics of a live-cell environment to uncover hidden druggable target sites across the entire human genome and then convert this information rapidly into novel small-molecule therapeutics.
Researchers at The Wistar Institute are developing high-throughput phenotypic assays for a multitude of undruggable targets of interest in cancer, aging and immunology, to which PhoreMost will apply SITESEEKER, in order to find new therapeutic options in these unmet disease areas. Wistar will also provide PhoreMost with specialist disease biology knowledge and drug mode-of-action studies on a project-by-project basis to support downstream drug discovery efforts.
Dr Torrance, CEO of PhoreMost, commented: “PhoreMost and Wistar share the belief that innovative small biotechs working together with nimble research institutes could represent a new model for drug discovery to increase the diversity of new therapies being developed and bring them to patients at lower costs. I am delighted the Wistar is a founding member in this mission and encourage other academic and clinical institutes to join us in this mission.”
Heather Steinman, Ph.D., M.B.A., Wistar vice president for Business Development and executive director, Technology Transfer, said: “PhoreMost is a cutting-edge discovery partner that will be collaborating closely with Wistar to uncover previously unidentified therapeutic targets that may prove useful for advancing innovative therapies. We are eager to be partnering with PhoreMost to fully utilize their phenotype-based screening platform technology to rapidly identify new therapeutic candidates.”
Feisty Fetal T Cells Can Rebel In UteroNews
Preterm labor, a common pregnancy complication, has long been a mystery to scientists. But a new study shows it may sometimes happen when the fetal immune system “wakes up” too early and begins to reject the mother, causing the uterus to start contracting.READ MORE
Investigating Inflammasomes Implicated in Diabetic RetinopathyNews
Team of researchers employ mouse model exhibiting diabetic retinopathy symptoms that could lead to future translational research studies.READ MORE
“Lymphoma Micro-reactor” Targets Chemo-Resistant LymphomaNews
Researchers have developed a “lymphoma micro-reactor” device that exposes human lymphomas to fluid flow similar to that in the lymphatics and parts of the lymph node.READ MORE
Comments | 0 ADD COMMENT
Asia Pacific Congress on Probiotics, Prebiotics and Nutrition
Oct 15 - Oct 16, 2018